Departments of Oncology, Biochemistry and Molecular & Cellular Biology, and Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine , Washington, DC , USA.
Department of Pharmacology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA.
Front Oncol. 2015 Jan 20;4:381. doi: 10.3389/fonc.2014.00381. eCollection 2014.
Radioprotectors are compounds that protect against radiation injury when given prior to radiation exposure. Mitigators can protect against radiation injury when given after exposure but before symptoms appear. Radioprotectors and mitigators can potentially improve the outcomes of radiotherapy for cancer treatment by allowing higher doses of radiation and/or reduced damage to normal tissues. Such compounds can also potentially counteract the effects of accidental exposure to radiation or deliberate exposure (e.g., nuclear reactor meltdown, dirty bomb, or nuclear bomb explosion); hence they are called radiation countermeasures. Here, we will review the general principles of radiation injury and protection and describe selected examples of radioprotectors/mitigators ranging from small-molecules to proteins to cell-based treatments. We will emphasize agents that are in more advanced stages of development.
辐射防护剂是指在辐射暴露前给予时可预防辐射损伤的化合物。缓解剂可在暴露后出现症状前给予,以预防辐射损伤。辐射防护剂和缓解剂可通过允许更高剂量的辐射和/或减少对正常组织的损伤,潜在地改善癌症治疗的放疗效果。这些化合物还可能抵消意外辐射暴露或故意暴露(例如,核反应堆熔毁、脏弹或原子弹爆炸)的影响;因此,它们被称为辐射对策。在这里,我们将回顾辐射损伤和防护的一般原则,并描述从小分子到蛋白质再到基于细胞的治疗等各种辐射防护剂/缓解剂的例子。我们将强调处于更高级开发阶段的制剂。